Overview of Ebastina Teva

Ebastina Teva is a pharmaceutical product containing the active ingredient Ebastine (INN), which is classified as a synthetic, second-generation antihistamine. Its fundamental identity is that of a highly selective Histamine H1-receptor antagonist, primarily intended for the systemic relief of allergic symptoms.

Quick Facts

Property	Description
Active ingredient	Ebastine (INN)
Form	Oral tablets (Film-coated, Orodispersible)
Pharmacological class	Second-Generation Antihistamine
Common use	Systemic anti-allergic relief
Origin	Synthetic (Piperidine derivative)

What Type of Medicine Is Ebastina Teva?

Ebastina Teva belongs to the pharmacological class of other antihistamines for systemic use with the ATC code R06AX22. This classification reflects that the Ebastine compound, a piperidine derivative, is highly selective for peripheral H1 receptors, which is the mechanism that results in a non-sedating profile compared to older antihistamines. The compound is used for its role in allergic disorders.

Forms and Composition of Ebastina Teva

The medicinal product is a single active ingredient product designed for oral administration. Ebastina Teva is available in multiple pharmaceutical preparations, including standard film-coated tablets and convenient orodispersible tablets, which dissolve quickly in the mouth without water. The active ingredient, Ebastine, is the sole pharmacologically active component, combined with necessary pharmaceutical excipients like lactose monohydrate to create the final oral dosage form.

What Is the General Purpose of Taking Ebastine?

The general purpose of this medication is to provide effective anti-allergic relief by directly counteracting the physiological effects of histamine. By selectively blocking the H1 receptors, Ebastine mitigates the processes that cause swelling, increased capillary permeability, and itching, which are the main physical manifestations of allergic reactions. This highly selective action provides sustained relief over a 24-hour period with convenient administration.

What side effects are possible with Ebastina Teva?

Possible side effects and safety information

This section describes the safety characteristics of Ebastina Teva (Ebastine) as documented in official government regulatory texts, summarizing the types and frequencies of adverse reactions observed in clinical use and post-marketing surveillance.

Adverse reactions are classified by frequency, based on regulatory standards:

Very Common (may affect more than 1 in 10 people): Headache.
Common (may affect up to 1 in 10 people): Somnolence (drowsiness) and Dry Mouth.
Rare (may affect up to 1 in 1,000 people): Effects on the Nervous System like dizziness, and Gastrointestinal Disorders such as nausea, vomiting, abdominal pain, and indigestion (dyspepsia). Rare effects also include Cardiac Disorders like palpitations and increased heart rate (tachycardia).

Reactions reported with a frequency of Not Known (based on post-marketing experience) include severe, clinically significant events. These affect the Immune System (e.g., severe hypersensitivity reactions like anaphylaxis and angioedema) and the Hepatobiliary System (e.g., hepatitis, cholestasis, or abnormal liver function tests).

Regulatory Safety Considerations

Official prescribing information includes specific cautions for certain patient populations. Caution is required for individuals with mild to moderate hepatic insufficiency or renal insufficiency. The medicine is generally contraindicated in cases of severe hepatic impairment. Furthermore, particular attention is paid to patients with known QTc interval prolongation or hypokalaemia.

Due to the possibility of somnolence or dizziness, the label notes that individuals should assess their personal reaction to the medicine before engaging in tasks that require focused attention, such as operating complex machinery. Caution is also advised regarding co-administration with other medicines that are known to either prolong the QTc interval or inhibit certain hepatic enzymes, specifically CYP450 3A4.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Ebastine overdose is focused on specific clinical effects observed at high doses and the required immediate emergency response. Patients who have taken an excessive amount of the medicinal product must contact a doctor immediately or go to the Emergency Department of the nearest hospital. This action is mandated even if no immediate signs of discomfort or poisoning are present.

Documented manifestations in the context of an acute overdose include signs of Central Nervous System (CNS) effects, such as somnolence (drowsiness), and antimuscarinic effects, such as dry mouth and accommodation disorders.

Of critical concern is the potential for cardiovascular effects, particularly the risk of QTc interval prolongation, which is a severe, dose-related outcome. Due to this risk, treatment requires immediate monitoring of vital functions, including continuous Electrocardiogram (ECG) monitoring.

Management of the acute overdose is limited to general procedural steps, as regulatory documents confirm that no specific antidote is known for Ebastine. Treatment, therefore, consists of providing symptomatic treatment and general supportive treatment, which may include procedures like gastric lavage.

Patients with known severe hepatic impairment (severe liver disease) have an altered metabolic capacity, which is a factor that may influence the severity and duration of the overdose effects.

Therapeutic Uses of Ebastina Teva

Main Uses of Ebastina Teva

Ebastina Teva is an antihistamine medication used primarily to manage symptoms associated with allergic reactions. Its active ingredient, ebastine, is a long-acting selective peripheral histamine H1 receptor antagonist. It is commonly utilized to address both seasonal and perennial allergic conditions.

Allergic Rhinitis

The medication is frequently indicated for the relief of symptoms caused by allergic rhinitis. This includes inflammation of the nasal passages triggered by allergens such as pollen (hay fever), dust mites, or pet dander. Patients using this treatment for rhinitis may find relief from:

Frequent sneezing
Nasal congestion or a runny nose
Itching of the nose
Watery, red, or itchy eyes

Allergic Conjunctivitis

In addition to nasal symptoms, Ebastina Teva is used to manage allergic conjunctivitis. This condition involves the inflammation of the lining of the eyelids and the white part of the eye, often occurring alongside rhinitis during allergy seasons.

Urticaria (Hives)

Ebastina Teva is also used for the symptomatic treatment of urticaria, more commonly known as hives. It helps reduce the physical manifestations of chronic idiopathic urticaria, which is characterized by the sudden appearance of itchy wheals or welts on the skin without an immediately identifiable cause.

Benefits and Mechanism

As a second-generation antihistamine, Ebastina Teva offers several characteristics beneficial for the management of chronic and acute allergic symptoms:

Selective Action: The medication specifically targets H1 receptors in the body's periphery, which helps neutralize the effects of histamine—the chemical responsible for allergy symptoms.
Duration of Effect: It is designed to provide prolonged relief, typically allowing for a simplified daily schedule.
Non-Sedating Profile: Unlike older antihistamines, ebastine has a limited ability to cross the blood-brain barrier. At standard therapeutic levels, it generally does not interfere with cognitive or psychomotor performance, although individual responses can vary.

Regulatory References

EMA Therapeutic Indications

Eligibility and Restrictions for Use

Who can and cannot use Ebastina Teva?

The eligibility for using Ebastina Teva is strictly defined by official regulatory documents based on age, pre-existing conditions, and physiological status.

Contraindications (Must Not Use)

The medicine is contraindicated for patients with a known hypersensitivity or allergy to the active substance, Ebastine, or to any of the product’s excipients. Additionally, some regulatory documents list severe hepatic impairment (severe liver disease) as an absolute contraindication for specific higher-dose formulations.

Age and Development Status

Ebastina Teva is approved for use in adults and adolescents aged 12 years and over. Use is not recommended in children under 12 years of age because the safety and efficacy in this population have not been established. No dose adjustment is required for older adults.

Condition-Based Restrictions

Use requires caution in patients with a known risk for QTc interval prolongation or hypokalaemia. For patients with severe hepatic impairment, regulatory documents mandate that the dose should not exceed 10 mg due to limited experience with higher doses. No dose adjustment is necessary for patients with any degree of renal impairment.

Pregnancy and Lactation

As a precautionary measure, use of Ebastine is preferable to avoid during both pregnancy and lactation due to limited or insufficient human data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ebastina is metabolized in the liver, primarily by the cytochrome P450 (CYP) enzyme system, specifically CYP3A4. This metabolic pathway makes it susceptible to pharmacokinetic interactions with other medicinal products that also utilize or inhibit this enzyme system.

Clinically Relevant Interactions

Interacting Product Category	Specific Examples	Mechanistic Basis
Potent CYP3A4 Inhibitors (e.g., Macrolide Antibiotics, Azole Antifungals)	Erythromycin, Clarithromycin, Ketoconazole, Itraconazole	These medicines can inhibit Ebastina's metabolism, leading to an increase in Ebastina plasma concentrations and a resulting potential for QT interval prolongation.
CYP3A4 Inducers	Rifampicin	This anti-tuberculosis agent can significantly induce Ebastina's metabolism, leading to a decrease in Ebastina plasma concentrations and a potential reduction in its antihistamine effect.
Other QTc-Prolonging Drugs	Certain Antiarrhythmics, other antihistamines	Concomitant use with drugs known to prolong the QT interval may increase the risk of cardiac effects, and is generally advised against for susceptible patients.

Other Interaction Notes

Central Nervous System (CNS) Depressants: In clinical studies, Ebastina did not demonstrate a synergistic sedative effect when combined with common CNS depressants, such as Diazepam or Alcohol, at therapeutic doses.
Food: Administration of Ebastina with food can increase the bioavailability of the drug but does not typically lead to a modification of its clinical effect.
Other Drugs without Reported Interaction: No significant interactions have been reported with medicinal products such as Theophylline, Warfarin, or Cimetidine.

Patients with known QTc interval prolongation, hypokalemia, or severe hepatic impairment should be monitored closely when Ebastina is co-administered with any of the interacting products listed above.

Mechanism of Action

Blocking the Histamine H1 Receptor

This medication primarily operates by acting as an antagonist at the Histamine H1 receptor, a protein located on the surface of various peripheral cells. By binding to and stabilizing this receptor in an inactive conformation , the drug prevents the body's natural histamine molecule from initiating its usual signaling cascade, thereby reducing the signaling initiated by histamine at the H1 receptor on the body’s physiological processes.

Peripheral Inhibition and Physiological Modulation

The active component of this drug exhibits a peripheral mechanism of action, meaning its key effects occur outside the central nervous system. This targeted interference with the histamine signaling pathway leads to physiological changes such as reduced vascular permeability and the modulation of certain tissue contractions. This core mechanism results in the deactivation of the H1-mediated signaling cascade within the affected peripheral pathways.

Dosage and Administration Information

Official Instructions for Administration

Ebastina Teva is designed for systemic use and is administered via the oral route. The medication is taken according to a strict once daily (OD) schedule, which supports its long duration of action. The tablets offer flexibility in administration as they can be taken with or without food.

Standard Dosing and Limits

The typical starting dosage for adults and adolescents 12 years and older is 10 mg once daily. In cases where more severe symptoms require greater support, the dose may be increased to 20 mg once daily. This 20 mg dose also represents the maximum recommended daily dose and should not be exceeded.

Administration Detail	Official Guideline
Dosing Frequency	Once Daily (OD)
Dose Range (Adults)	10 mg to 20 mg
Relation to Meals	With or without food

Form-Specific Instructions

The medicinal product is available as film-coated tablets, which are swallowed whole with liquid, and as orodispersible tablets. The latter must be placed directly on the tongue, where they dissolve rapidly, allowing them to be taken without water.

Population Adjustments

Dose adjustments are generally not necessary for older adults or patients with renal impairment. However, a critical restriction applies to patients with severe hepatic impairment: in this population, the dose must not exceed 10 mg once daily. The duration of use is determined by the course of the patient's condition.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ebastina Teva

Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Research exploring the use of Ebastina Teva for allergic rhinitis—a condition characterized by fluctuating or episodic manifestations—has been based primarily on Randomized Controlled Trials (RCTs). These short-term and intermediate-term studies were used to compare the compound against both an inactive substance (placebo) and other treatments evaluated in similar trials. The studies typically involved adults and adolescents (aged 12 years and older) who had already received a diagnosis of seasonal or year-round allergies.

The research examined outcomes related to physical discomfort by measuring changes in specific symptoms. These outcomes included the Total Nasal Symptom Score (TNSS), which monitors factors like sneezing, runny nose, and nasal itching. Studies also explored outcomes reflecting daily functioning or activity level by using quality of life scales to understand how the condition impacted daily functioning. Data show patterns related to measured changes in symptom scores for the study participants that were observed to be different from the symptom patterns seen in those receiving the placebo. Comparative research describes that changes measured during the study period were observed to be consistent with those documented for other compounds evaluated in similar trials.

The evidence landscape is broadly defined by published studies, but some gaps exist. Specifically, the data for nasal congestion is not as consistently documented across all major trials as the data for itching and sneezing. Furthermore, the follow-up durations were limited in many core efficacy trials, meaning that while research provides insight into short-term changes, the long-term effects are not fully established by controlled studies.

Evidence for Use in Chronic Idiopathic Urticaria (Chronic Hives)

The compound was studied for use in a research context involving conditions characterized by fluctuating or episodic manifestations such as Chronic Idiopathic Urticaria (CIU). The research primarily consisted of Randomized Controlled Trials (RCTs) that involved adults who had active, ongoing symptoms of chronic hives. Studies monitored outcomes related to physical discomfort by measuring the change in the severity of itching (pruritus) and the change in the number and size of visible wheals (hives).

Studies reported how symptoms evolved in the observed populations over defined time intervals, typically ranging from a few weeks up to three months. Research describes that data show patterns related to changes in measured itching severity and wheal counts was observed in some studies during the defined time intervals. This evidence contributes to understanding symptom patterns in a patient group where symptoms may vary in intensity.

Data for certain groups remain insufficient for specific subtypes of hives other than CIU. Most core trials focus narrowly on CIU, meaning that comparative evidence or data on effectiveness for inducible urticaria (hives triggered by specific stimuli like cold or pressure) are largely lacking in the main regulatory summaries. Additionally, some comparative evidence is lacking in terms of large, direct head-to-head trials against all available modern antihistamines for all measured endpoints.

Long-Term Studies and Durability of Follow-up

Research explored the sustained observation of symptom patterns for periods beyond the standard short-term efficacy trials. While many core RCTs only cover two to four weeks, subsequent trials and observational research studies explored follow-up durations to assess outcomes over intervals of up to 12 weeks for the conditions studied.

These longer studies was observed in observational settings evaluating daily-life functioning and monitoring outcomes related to physical discomfort. Research describes that data show patterns related to symptom-scores was observed in some studies during the maintenance phase. However, long-term effects are not fully established beyond the three-month mark by the highest-quality, double-blind RCTs, meaning that data for certain groups remain insufficient when evaluating outcomes over periods exceeding six months or one year.

Evidence in Specific Patient Populations

Ebastina Teva was studied for use across a defined age range, with primary regulatory evidence focusing on adults and adolescents aged 12 years and older. The evidence base includes specific analyses for the adolescent population within these larger trials.

However, the research highlights that there are limited data for certain groups. For instance, data for children under 12 years old are much less extensive in the formal regulatory summaries than data for the core adult and adolescent populations. Furthermore, while older adults were often included in clinical studies, the research does not always provide separate, detailed information regarding outcomes or patterns observed specifically in this demographic or in individuals with significant pre-existing health conditions (comorbidities).

What is Still Uncertain About the Research for Ebastina Teva

The body of research, while documenting patterns observed in the studies in key study populations, still contains areas of uncertainty.

Long-term effects are not fully established by the core controlled research, particularly for use extending beyond three months.
Comparative evidence is lacking for certain endpoints when looking at direct comparisons against all available second-generation antihistamines. Findings were sometimes mixed when comparing measurements of individual symptoms between the active medication and other standard therapies.
Data for certain groups remain insufficient, especially for children under 12, or in patients presenting with specific, non-idiopathic subtypes of chronic hives.
It is important to understand that the study results reflect the specific conditions under which they were conducted, and research does not determine whether an individual will respond similarly outside of the clinical trial setting. Findings describe group patterns, not personal outcomes.

Frequently Asked Questions (FAQ)

Common questions about Ebastina Teva (FAQ)

Q: How does Ebastina Teva interact with alcohol?

A: Official product information, based on clinical studies, indicates that this medicine did not show a synergistic sedative effect when combined with alcohol at therapeutic doses. Despite this finding, patients are generally advised to consult with a healthcare professional regarding any medication and alcohol consumption.

Q: Can children under 12 take Ebastina Teva?

A: Regulatory documents state that Ebastina Teva is approved for use in adults and adolescents aged 12 years and over. For children under 12 years of age, the safety and effectiveness of this medicine have not been established in the formal regulatory summaries.

Q: What side effects are common with Ebastina Teva?

A: According to the official product information, common side effects are those that may affect up to 1 in 10 people. The most common reactions reported are dry mouth, somnolence (drowsiness), and headache.

Q: What conditions is Ebastina Teva used to treat?

A: The official product information states that this medicine is indicated for the symptomatic relief of specific allergic conditions. This includes seasonal and perennial allergic rhinitis (hay fever or year-round allergies) or rhinoconjunctivitis, as well as chronic urticaria (hives).

Q: What should I do if I miss a dose of Ebastina Teva?

A: Official patient information describes the recommended approach if a dose is missed. The instruction is to take the dose as soon as it is remembered. However, if it is nearly time for the next dose, the missed dose is to be skipped, and the regular schedule continued. It is explicitly stated that two doses should not be taken at the same time.

Q: How long does it take for Ebastina Teva to start working?

A: The onset of effect is related to how quickly the medicine is absorbed by the body. Pharmacokinetic studies indicate that peak blood levels of the drug's active component are typically observed between 2.6 to 4 hours after taking a dose.

Q: Does this medicine contain lactose?

A: Official regulatory documents caution that some formulations of this medicine, such as the orodispersible tablets, contain lactose monohydrate. Official product information notes that due to the presence of lactose, this medicine is restricted for use in patients with rare hereditary problems such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption.

Q: Can pregnant women use Ebastina Teva?

A: Official regulatory prescribing information advises that, as a precautionary measure, it is preferable to avoid the use of this medicine during pregnancy. This caution is stated due to the limited or insufficient human data available regarding its safety during this period.

Q: What is the difference between film-coated and orodispersible tablets?

A: Official instructions for administration detail the different ways these two forms are taken. The film-coated tablets are designed to be swallowed whole with liquid. In contrast, the orodispersible tablets are formulated to be placed directly on the tongue, where they rapidly dissolve, allowing them to be taken without water.

How should Ebastina Teva be stored and disposed of?

How to Store and Dispose of Ebastina Teva

Storage and disposal must strictly adhere to regulatory labeling to maintain product integrity and ensure safety.

Official Storage Requirements

Specific storage conditions apply to different formulations. Some Ebastina Teva tablets may require storage not above 25 C, while others have no special storage conditions listed. All formulations must be kept out of the sight and reach of children. The orodispersible tablets must be stored in the original packaging to protect from light and should not be used past the expiry date stated on the carton.

Official Disposal Instructions

Do not dispose of this medicine via wastewater or household waste. Unused or expired Ebastina Teva must be disposed of at a pharmacist or an officially recognized medicine collection point, following local regulations.

Ebastina Teva